The Texas Interprofessional Pharmacogenomics (IPGx)

Conditions

• Adverse Drug Reaction

Eligibility Criteria

Sex

ALL

Age

45 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.

Key Dates

Start date

Dec 15, 2021

Status verified

Aug 2025

Primary completion

Nov 30, 2026

Completion

Nov 30, 2027

Study Design

Enrollment

50 participants (estimated)

Primary Outcome Measure

Frequency and nature of ADRs on the Naranjo Scale [ Time Frame: 180 days ]

Central Contacts

• Kenneth S Ramos, MD
  7136777740
  [email protected]

Locations (1)

Find similar trials in Bryan, TX